Copyright © 2018 ALM Media Properties, LLC. All Rights Reserved.
The Delaware Supreme Court on Tuesday narrowly upheld a Delaware Court of Chancery ruling that denied a $50 million bonus payment to former investors in Calistoga Pharmaceuticals Inc. for partial European approval of a new blood-cancer treatment drug.
*May exclude premium content
Already have an account? Sign In Now
Interested in customizing your subscription with Law.com All Access?
Contact our Sales Professionals at 1-855-808-4530 or send an email to firstname.lastname@example.org to learn more.
Tom McParland of Delaware Law Weekly can be contacted at 215-557-2485 or at email@example.com. Follow him on Twitter @TMcParlandTLI.